Btained in NSABP B, treatment with doxorubicin
and cyclophosphamide with or without paclitaxel. Demonstrated its ixabepilone Antitumoraktivit t In TNBC was both when used alone or in combination with CYC202 Roscovitine capecitabine. When used as monotherapy, Hte ixabepilone induced pCR increased in TNBC group compared to patients without TNBC or the entire study population of patients Several phase II and III for ixabepilone, s efficiency in combination with capecitabine, second-line therapy far widely used in anthracycline and taxane-resistant disease. The pooled analysis of these studies showed that the response rate and progression-free survival time for patients has been improved U TNBC combination treatment than those U capecitabine monotherapy again contrary.
Ongoing studies examining the activity T ixabepilone in combination with sunitinib, cetuximab and direct comparison with docetaxel and paclitaxel-containing regimens. Ixabepilone has been shown that a manageable safety profile, neutropenia, sensory neuropathy, fatigue, joint pain, muscle Lapatinib pain, stomatitis and its main side effects. Targeted therapy PARP inhibitors Pr Led clinical data on the mechanisms of PARP inhibitors for early-stage clinical trials in the targeted treatment of breast cancer and BRCA deficient TNBC. This class of drugs includes Olaparib, iniparib and veliparib. PARP inhibitors following are studied in various stages of clinical trials. Olaparib, an oral PARP and PARP is active in BRCA deficient ovarian and breast cancer. In Phase I and II studies showed Olaparib monotherapy anti-tumor activity t in tears liked the BRCA mutations with disease refractory or advanced.
A h Here rate of partial response to Olaparib was in patients without TNBC TNBC patients demonstrated. The toxicity th Were observed prim R and variety and were Similar to those observed with herk Mmlicher chemotherapy. Encouraging as these results are, it remains unclear whether Olaparib effective au’s outside the BRCA associated cancer. Canadian study, a phase II study in four cohorts of patients with advanced breast and ovarian cancer based closed arm sporadic TNBC patients with no response to treatment was observed Olaparib. The efficacy in combination with Olaparib herk Mmlichen chemotherapy has not yet been determined. Trends in toxicity t Due to the fact that the drug with paclitaxel in the treatment of metastatic triple negative is united.
In view of the pr-Clinical data suggest that PARP inhibition may potentiate the effects of platinum compounds, Olaparib is being tested in combination with carboplatin and cisplatin in TNBC. Safety data from these studies will be important in determining Olaparib, the place of therapy in TNBC. Iniparib intravenously is a PARP inhibitor S administered. Add iniparib with gemcitabine and carboplatin in a phase II study in metastatic triple-negative laughed ngerte Median overall survival. Months. Months, which. To a reduction in risk of death The median PFS in the group was iniparib. Month passed. Months in the chemotherapy group. No significant difference in adverse events between the groups was observed. These promising results pave the way for a phase III study evaluating OS and PFS metastatic triple negative.